Valneva

Valneva Tangible Book Value per Share

The Tangible Book Value per Share of Valneva (VLA.PA) as of Oct 21, 2026 is 0.69 EUR. In the previous year, Tangible Book Value per Share was 1.02 EUR — a change of -31.94% (lower).

Tangible Book Value per Share

0.69EUR

YoY

-31.94%

Last updated:

Tangible Book Value per Share of Valneva is 2025 0.69 EUR. Tangible Book Value per Share of Valneva was 2024 1.02 EUR. It decreases by -31.94% lower compared to the previous year.

The Valneva Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
0.64 EUR
Jan 1, 2019
0.61 EUR
Jan 1, 2020
0.27 EUR
Jan 1, 2021
0.90 EUR
Jan 1, 2022
1.25 EUR
Jan 1, 2023
0.67 EUR
Jan 1, 2024
1.02 EUR
Jan 1, 2025
0.69 EUR
The Valneva Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
0.69EUR-31.94%
1.02EUR+51.92%
0.67EUR-46.27%
1.25EUR+38.59%
0.90EUR+228.19%
0.27EUR-54.99%
0.61EUR-5.04%
0.64EUR+122.38%
0.29EUR+7.57%
0.27EUR-10.22%
0.30EUR+137.88%
0.13EUR-59.25%
0.31EUR-6.91%
0.33EUR-57.21%
0.77EUR-29.96%
1.11EUR+31.96%
0.84EUR-21.47%
1.07EUR-10.47%
1.19EUR+3,076.80%
0.04EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Tangible Book Value per Share of Valneva is 0.69 EUR in 2025.

Tangible Book Value per Share of Valneva changed from 1.02 EUR to 0.69 EUR, representing a -31.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Valneva since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Valneva

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Valneva